1 PREFACE
1.1. Introduction
1.2. Report Coverage
1.3. Market Segmentation
1.4. Key Market Insights
1.5. Market Share Insights
1.6. Key Questions Answered
2 RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3 ECONOMIC AND OTHER PROJECT-SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4 MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Value and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
5.1. Liquid Biopsy Solutions: Market Landscape
5.2. Liquid Biopsy Solutions: Market Trends
5.3. Liquid Biopsy Solutions: Market Forecast and Opportunity Analysis
6. INTRODUCTION
6.1. Chapter Overview
6.2. Cancer Statistics and Burden of the Disease
6.3. Importance of Early Cancer Detection
6.4. Cancer Screening and Diagnosis
6.5. Conventional Invasive Cancer Diagnostic Tests
6.5.1. Biopsy
6.5.2. Fine Needle Aspiration Biopsy
6.5.3. Core Needle Aspiration Biopsy
6.5.4. Vacuum-Assisted Biopsy
6.5.5. Image Guided Biopsy
6.5.6. Sentinel Node Biopsy
6.5.7. Surgical Biopsy
6.5.8. Endoscopic Biopsy
6.5.9. Bone Marrow Biopsy
6.5.10. Endoscopy
6.6. Need for Non-Invasive Approaches
6.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
6.7.1. Circulating Tumor Cells
6.7.2. Circulating Tumor DNA / Cell Free DNA
6.7.3. Exosomes
6.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests
6.9. Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics
6.10. Challenges Associated with Non-Invasive Cancer Diagnostics
6.11. Future Perspectives
7. CASE-STUDY: NON-INVASIVE CANCER SCREENING AND DIAGNOSIS
7.1. Chapter Overview
7.2. Diagnostic Imaging
7.2.1. Magnetic Resonance Imaging (MRI)
7.2.2. Mammography
7.2.3. Bone Scan
7.2.4. Computerized Tomography (CT) Scan
7.2.5. Integrated Positron Emission Tomography (PET)- CT Scan
7.2.6. Ultrasound
7.2.7. X-ray Radiography (Barium Enema)
7.3. Screening Assays
7.3.1. Circulating Tumor Marker Test
7.3.2. Digital Rectal Exam (DRE)
7.3.3. Fecal Occult Blood Test (FOBT)
7.3.4. Multigated Acquisition (MUGA) Scan
7.3.5. Papanicolaou Test and Human Papilloma Virus Test
7.4. Advanced Non-Invasive Approaches
7.4.1. Cytogenetic / Gene Expression Studies
7.4.2. Molecular Signature-based Non-Invasive Methods
7.4.3. Saliva-based Oral Cancer Diagnostics
7.4.4. Vital Staining
7.4.5. Optical Biopsy
7.4.6. Other Diagnostic Techniques
8. MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Liquid Biopsy Solutions: Overall Market Landscape
8.2.1. Analysis by Stage of Development
8.2.2. Analysis by Type of Solution
8.2.3. Analysis by Type of Technology
8.2.4. Analysis by Type of Sample
8.2.5. Analysis by Type of Circulating Biomarker
8.2.6. Analysis by Type of Cancer
8.2.7. Analysis by Solution Purpose
8.2.8. Analysis by Application Area
8.3. Liquid Biopsy Market: Overall Developer Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.3.4. Analysis by Most Active Players
9. PRODUCT COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Overview of Peer Groups
9.4.1. Peer Group I: Overview of Liquid Biopsy Assay Kits
9.4.2. Peer Group II: Overview of Liquid Biopsy Devices
9.4.3. Peer Group III: Overview of Liquid Biopsy Software and Other Solutions
9.5. Product Competitiveness Analysis
9.5.1. Liquid Biopsy Assay Kits
9.5.1.1. Liquid Biopsy Assay Kits Offered by Providers Based in North America
9.5.1.2. Liquid Biopsy Assay Kits Offered by Providers Based in Europe
9.5.1.3. Liquid Biopsy Assay Kits Offered by Providers Based in Asia-Pacific and RoW
9.5.2. Liquid Biopsy Devices
9.5.2.1. Liquid Biopsy Assay Kits Offered by Providers Based in North America
9.5.2.2. Liquid Biopsy Assay Kits Offered by Providers Based in Europe
9.5.2.3. Liquid Biopsy Assay Kits Offered by Providers Based in Asia-Pacific and RoW
9.5.3. Liquid Biopsy Software and Other Solutions
9.5.3.1. Liquid Biopsy Software and Other Solutions Offered by Providers
10. COMPANY PROFILES: LIQUID BIOPSY SOLUTION PROVIDERS
10.1. Chapter Overview
10.2. Amoy Diagnostics
10.2.1. Company Overview
10.2.2. Liquid Biopsy Portfolio
10.3. BioCartis
10.3.1. Company Overview
10.3.2. Liquid Biopsy Portfolio
10.4. DiaCarta
10.4.1. Company Overview
10.4.2. Liquid Biopsy Portfolio
10.5. Exact Sciences
10.5.1. Company Overview
10.5.2. Liquid Biopsy Portfolio
10.6. Gencurix
10.6.1. Company Overview
10.6.2. Liquid Biopsy Portfolio
10.7. Genecast Biotechnology
10.7.1. Company Overview
10.7.2. Liquid Biopsy Portfolio
10.8. Integrated DNA Technologies
10.8.1. Company Overview
10.8.2. Liquid Biopsy Portfolio
10.9. Lucence Diagnostics
10.9.1. Company Overview
10.9.2. Liquid Biopsy Portfolio
10.10. MedGenome
10.10.1. Company Overview
10.10.2. Liquid Biopsy Portfolio
10.11. Medicover Genetics
10.11.1. Company Overview
10.11.2. Liquid Biopsy Portfolio
10.12. nRichDx
10.12.1. Company Overview
10.12.2. Liquid Biopsy Portfolio
10.13. Precipio
10.13.1. Company Overview
10.13.2. Liquid Biopsy Portfolio
10.14. Qiagen
10.14.1. Company Overview
10.14.2. Liquid Biopsy Portfolio
10.15. RGCC
10.15.1. Company Overview
10.15.2. Liquid Biopsy Portfolio
10.16. ScreenCell
10.16.1. Company Overview
10.16.2. Liquid Biopsy Portfolio
10.17. Singlera Genomics
10.17.1. Company Overview
10.17.2. Liquid Biopsy Portfolio
10.18. Thermo Fisher Scientific
10.18.1. Company Overview
10.18.2. Liquid Biopsy Portfolio
11 PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Liquid Biopsy Solutions: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Type of Partner
11.3.5. Analysis by Type of Circulating Biomarker
11.3.6. Analysis by Type of Cancer
11.3.7. Most Active Players: Analysis by Number of Partnerships
11.3.8. Analysis by Geography
11.3.8.1. Local and International Agreements
11.3.8.2. Intercontinental and Intracontinental Agreements
12 FUNDING AND INVESTMENTS
12.1. Chapter Overview
12.2. Funding Models
12.3. Liquid Biopsy Solutions: Funding and Investments
12.3.1. Analysis by Year of Funding
12.3.1.1. Cumulative Year-wise Trend of Funding Instances
12.3.1.2. Cumulative Year-wise Trend of Amount Invested
12.3.2. Analysis by Type of Funding
12.3.2.1. Analysis by Funding Instances
12.3.2.2. Analysis of Amount Invested by Year and Type of Funding
12.3.3. Analysis by Year and Type of Funding
12.3.4. Analysis by Type of Circulating Biomarker
12.3.5. Analysis by Type of Cancer
12.3.6. Analysis by Application Area
12.3.7. Most Active Players: Analysis by Number of Funding Instances
12.3.8. Most Active Players: Analysis by Amount Raised
12.3.9. Leading Investors by Number of Funding Instances
12.3.10. Analysis by Geography
13 BIG PHARMA INITIATIVES
13.1. Chapter Overview
13.2. Liquid Biopsy: List of Initiatives Undertaken by Big Players
13.2.1. Analysis by Year of Initiative
13.2.2. Analysis by Type of Initiative
13.2.3. Analysis by Year and Type of Initiative
13.2.4. Analysis of Big Pharma Players by Number of Initiatives
13.2.5. Analysis by Type of Partnership
13.2.6. Analysis of Big Pharma Player by Type of Initiative
13.2.7. Analysis of Big Pharma Player by Year of Initiative
13.2.8. Big Pharma Initiatives Summary
14 KEY ACQUISITION TARGETS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Scoring Criteria and Key Assumptions
14.4. Potential Acquisition Targets: Liquid Biopsy Solution Providers
14.5. Concluding Remarks
15 CASE STUDY: OTHER NON-INVASIVE CANCER DIAGNOSTICS
15.1. Chapter Overview
15.2. Non-Blood-based Biomarker Detection Tests
15.3. Fecal Occult Blood Test (FOBT) and Fecal Immunochemical Tests (FIT)
15.4. Pigmented Lesion Assays
15.5. Stool DNA (sDNA)-based Tests
15.6. Volatile Organic Compound (VOC) Detection Tests
15.7. List of Other Non-Invasive Cancer Diagnostics
16 MARKET IMPACT ANALYSIS
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion
17 GLOBAL LIQUID BIOPSY MARKET
17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Global Liquid Biopsy Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.3.1. Scenario Analysis
17.3.1.1. Conservative Scenario
17.3.1.2. Optimistic Scenario
17.4. Key Market Segmentations
18 LIQUID BIOPSY MARKET, BY TYPE OF TECHNOLOGY
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Liquid Biopsy Market: Distribution By Type of Technology
18.3.1. Liquid Biopsy Market for Next Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.3.2. Liquid Biopsy Market for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.4. Data Triangulation and Validation
19 LIQUID BIOPSY MARKET, BY TYPE OF SAMPLE
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Liquid Biopsy Market: Distribution By Type of Sample
19.3.1. Liquid Biopsy Market for Blood, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.3.2. Liquid Biopsy Market for Other Samples, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.4. Data Triangulation and Validation
20 LIQUID BIOPSY MARKET, BY TYPE OF CIRCULATING BIOMARKER
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Liquid Biopsy Market: Distribution By Type of Circulating Biomarker
20.3.1. Liquid Biopsy Market for Circulating Tumor DNA, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.3.2. Liquid Biopsy Market for Cell Free DNA, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.3.3. Liquid Biopsy Market for Cell Free RNA, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.3.4. Liquid Biopsy Market for Exosomes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.3.5. Liquid Biopsy Market for Other Circulating Biomarkers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.4. Data Triangulation and Validation
21 LIQUID BIOPSY MARKET, BY TYPE OF CANCER
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Liquid Biopsy Market: Distribution By Type of Cancer
21.3.1. Liquid Biopsy Market for Breast Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.2. Liquid Biopsy Market for Colorectal Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.3. Liquid Biopsy Market for Prostate cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.4. Liquid Biopsy Market for Lung Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.5. Liquid Biopsy Market for Bladder Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.6. Liquid Biopsy Market for Melanoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.7. Liquid Biopsy Market for Thyroid Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.8. Liquid Biopsy Market for Gastric Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.9. Liquid Biopsy Market for Head and Neck Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.10. Liquid Biopsy Market for Leukemia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.11. Liquid Biopsy Market for Brain Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.12. Liquid Biopsy Market for Liver Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.13. Liquid Biopsy Market for Cervical Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.14. Liquid Biopsy Market for Ovarian Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.15. Liquid Biopsy Market for Oesophagus Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.16. Liquid Biopsy Market for Pancreatic Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.17. Liquid Biopsy Market for Nasopharyngeal cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.18. Liquid Biopsy Market for Sarcoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.4. Data Triangulation and Validation
22 LIQUID BIOPSY MARKET, BY APPLICATION AREA
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Liquid Biopsy Market: Distribution By Application Area
22.3.1. Liquid Biopsy Market for Early Diagnosis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
22.3.2. Liquid Biopsy Market for Patient Monitoring, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
22.3.3. Liquid Biopsy Market for Recurrence Monitoring, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation
23 LIQUID BIOPSY MARKET, BY END-USER
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Liquid Biopsy Market: Distribution By End-user
23.3.1. Liquid Biopsy Market for Hospitals / Laboratories, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
23.3.2. Liquid Biopsy Market for Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
23.3.3. Liquid Biopsy Market for Other End-users, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
23.4. Data Triangulation and Validation
24 LIQUID BIOPSY MARKET, BY GEOGRAPHICAL REGIONS
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Liquid Biopsy Market: Distribution By Geographical Regions
24.3.1. Liquid Biopsy Market for North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.3.3.1 Liquid Biopsy Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.3.2. Liquid Biopsy Market for Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.3.2.1 Liquid Biopsy Market in the France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.3.2.2 Liquid Biopsy Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.3.2.3 Liquid Biopsy Market in the Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.3.2.4 Liquid Biopsy Market in the Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.3.2.5 Liquid Biopsy Market in the Spain, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.3.3. Liquid Biopsy Market for Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.3.3.1 Liquid Biopsy Market in the China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.3.3.2 Liquid Biopsy Market in the India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.3.3.3 Liquid Biopsy Market in the Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.3.3.4 Liquid Biopsy Market in the Australia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.4. Market Dynamics Assessment
24.4.1. Market Movement Analysis
24.4.2. Penetration-Growth (P-G) Matrix
24.5. Data Triangulation and Validation
25 CONCLUDING REMARKS
25.1 Chapter Overview
26 EXECUTIVE INSIGHTS
26.1. Chapter Overview
26.2. Company A
26.2.1. Interview Transcript: Director
26.3. Company B
26.3.1. Interview Transcript: Innovation Director
26.4. Company C
26.4.1. Interview Transcript: Founder & Chief Executive Officer
26.5. Company D
26.5.1. Interview Transcript: President and Chief Technology Officer
26.6. Company E
26.6.1. Interview Transcript: Strategic Technology Advisor
26.7. Company F
26.7.1. Interview Transcript: Founder And Medical Director
26.8. Company G
26.8.1. Interview Transcript: Chief Executive Officer
26.9. Company H
26.9.1. Interview Transcript: Chief Operating Officer
26.10. Company I
26.10.1. Interview Transcript: Chief Medical Officer
26.11. Company J
26.11.1. Interview Transcript: President and Chief Executive Officer
26.12. Company K
26.12.1. Interview Transcript: Sales and Marketing Manager
26.13. Company L
26.13.1. Interview Transcript: Marketing Director
26.14. Company M
26.14.1. Interview Transcript: Founder
26.15. Company N
26.15.1. Interview Transcript: Chief Executive Officer
26.16. Company O
26.16.1. Interview Transcript: Chief Scientific Officer
26.17. Company P
26.17.1. Interview Transcript: Chief Executive Officer and Co-founder
26.18. Company Q
26.18.1. Interview Transcript: Chief Scientific Officer
List of Tables
Table 6.1 Survival on Early Diagnosis of Cancer
Table 6.2 Cost of Biopsy for Different Cancer Indications (USD)
Table 6.3 Common Conventional Endoscopic Procedures
Table 7.1 Examples of Tumor Markers
Table 8.1 Liquid Biopsy Solutions: Information on Stage of Development and Type of Solution
Table 8.2 Liquid Biopsy Solutions: Information on Type of Technology and Type of Sample
Table 8.3 Liquid Biopsy Solutions: Information on Type of Circulating Biomarker, Type of Cancer
Table 8.4 Liquid Biopsy Solutions: Information on Solution Purpose and Application Area
Table 8.5 Liquid Biopsy Solutions: Information on Year of Establishment, Company Size and Location of Headquarters
Table 9.1 Product Competitiveness Scores Allotted to Liquid Biopsy Assay Kits Offered by Providers based in North America
Table 9.2 Product Competitiveness Scores Allotted to Liquid Biopsy Assay Kits Offered by Providers based in Europe
Table 9.3 Product Competitiveness Scores Allotted to Liquid Biopsy Assay Kits Offered by Providers based in Asia- Pacific and RoW
Table 9.4 Product Competitiveness Scores Allotted to Liquid Biopsy Devices Offered by Providers based in North America
Table 9.5 Product Competitiveness Scores Allotted to Liquid Biopsy Devices Offered by Providers based in Europe
Table 9.6 Product Competitiveness Scores Allotted to Liquid Biopsy Devices Offered by Providers based in Asia- Pacific and RoW
Table 9.7 Product Competitiveness Scores Allotted to Liquid Biopsy Software and Other Solutions
Table 10.1 Liquid Biopsy Solution Providers: List of Companies Profiled
Table 10.2 Amoy Diagnostics: Company Overview
Table 10.3 Amoy Diagnostics: Pipeline Overview
Table 10.4 BioCartis: Company Overview
Table 10.5 BioCartis: Pipeline Overview
Table 10.6 DiaCarta: Company Overview
Table 10.7 Diacarta: Pipeline Overview
Table 10.8 Exact Sciences: Company Overview
Table 10.9 Exact Sciences: Pipeline Overview
Table 10.10 GenCurix: Company Overview
Table 10.11 GenCurix: Pipeline Overview
Table 10.12 GeneCast Biotechnology: Company Overview
Table 10.13 GeneCast Biotechnology: Pipeline Overview
Table 10.14 Integrated DNA Technologies: Company Overview
Table 10.15 Integrated DNA Technologies: Pipeline Overview
Table 10.16 Lucence Diagnostics: Company Overview
Table 10.17 Lucence Diagnostics: Pipeline Overview
Table 10.18 MedGenome: Company Overview
Table 10.19 MedGenome: Pipeline Overview
Table 10.20 Medicover Genetics: Company Overview
Table 10.21 Medicover Genetics: Pipeline Overview
Table 10.22 nRICH Dx: Company Overview
Table 10.22 nRICH Dx: Pipeline Overview
Table 10.23 Precipio: Company Overview
Table 10.24 Precipio: Pipeline Overview
Table 10.25 Qiagen: Company Overview
Table 10.26 Qiagen: Pipeline Overview
Table 10.27 RGCC group: Company Overview
Table 10.28 RGCC group: Pipeline Overview
Table 10.29 Screen Cell: Company Overview
Table 10.30 Screen Cell: Pipeline Overview
Table 10.31 Singlera Genomics: Company Overview
Table 10.32 Singlera Genomics: Pipeline Overview
Table 10.33 Thermo Fisher Scientific: Company Overview
Table 10.34 Thermo Fisher Scientific: Pipeline Overview
Table 11.1 Liquid Biopsy Solutions: List of Partnerships and Collaborations
Table 11.2 Liquid Biopsy: Partnerships and Collaborations: Information on Type of Agreement (Country and Region), Type of Cancer, Type of Circulating Biomarker, 2020-2025
Table 12.1 Liquid Biopsy: List of Funding and Investments
Table 13.1 Big Pharma Players: List of Liquid Biopsy Focused Initiatives
Table 14.1 Liquid Biopsy Market: List of Key Acquisitions
Table 14.2 Liquid Biopsy Solution Providers: Likely Acquisition Targets
Table 16.1 Growth Drivers: Market Impact and Time Period
Table 16.2 Growth Restraints: Market Impact and Time Period
Table 16.3 Growth Opportunities: Market Impact and Time Period
Table 16.4 Growth Challenges: Market Impact and Time Period
Table 27.1 Liquid Biopsy: Distribution by Stage of Development
Table 27.2 Liquid Biopsy: Analysis by Type of Solution
Table 27.3 Liquid Biopsy: Analysis by Type of Technology
Table 27.4 Liquid Biopsy: Analysis by Type of Sample
Table 27.5 Liquid Biopsy: Analysis by Type of Circulating Biomarker
Table 27.6 Liquid Biopsy: Analysis by Type of Cancer
Table 27.7 Liquid Biopsy: Analysis by Solution Purpose
Table 27.8 Liquid Biopsy: Analysis by Application Area
Table 27.9 Liquid Biopsy Solution Providers: Distribution by Year of Establishment
Table 27.10 Liquid Biopsy Solution Providers: Distribution by Company Size
Table 27.11 Liquid Biopsy Solution Providers: Distribution by Location of Headquarters
Table 27.12 Liquid Biopsy Solution Providers: Distribution by Most Active Players
Table 27.13 Product Competitiveness Analysis: Overview of Liquid Biopsy Assay Kits (Peer Group I)
Table 27.14 Product Competitiveness Analysis: Overview of Liquid Biopsy Devices (Peer Group II)
Table 27.15 Product Competitiveness Analysis: Overview of Liquid Biopsy Software and Other Solution (Peer Group III)
Table 27.16 Product Competitiveness Analysis: Liquid Biopsy Assay Kits Offered by Providers based in North America
Table 27.17 Product Competitiveness Analysis: Liquid Biopsy Assay Kits Offered by Providers based in Europe
Table 27.18 Product Competitiveness Analysis: Liquid Biopsy Assay Kits Offered by Providers based in Asia- Pacific and RoW
Table 27.19 Product Competitiveness Analysis: Liquid Biopsy Devices Offered by Providers based in North America
Table 27.20 Product Competitiveness Analysis: Liquid Biopsy Devices Offered by Providers based in Europe
Table 27.21 Product Competitiveness Analysis: Liquid Biopsy Devices Offered by Providers based in Asia Pacific and RoW
Table 27.22 Product Competitiveness Analysis: Liquid Biopsy Software and Other Solutions
Table 27.23 Partnerships and Collaborations: Distribution by Year of Partnership
Table 27.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 27.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 27.26 Partnerships and Collaborations: Distribution by Type of Partner
Table 27.27 Partnerships and Collaborations: Distribution by Type of Circulating Biomarker
Table 27.28 Partnerships and Collaborations: Distribution by Type of Cancer
Table 27.29 Partnerships and Collaborations: Most Active Players: Distribution by Number of Partnerships
Table 27.30 Partnerships and Collaborations: Local and International Agreements
Table 27.31 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 27.32 Funding and Investment Analysis: Cumulative Year- wise Distribution of Funding Instances, Pre-2020-2025
Table 27.33 Funding and Investment Analysis: Cumulative Year- wise Distribution by Amount Invested, Pre-2020-2025 (USD Million)
Table 27.34 Funding and Investment Analysis: Distribution by Type of Funding
Table 27.35 Funding and Investment Analysis: Distribution of Amount Invested
Table 27.36 Funding and Investment Analysis: Distribution by Year and Type of Funding, Pre 2020-2025
Table 27.37 Funding and Investment Analysis: Distribution by Type of Circulating Biomarker
Table 27.38 Funding and Investment Analysis: Distribution by Type of Cancer
Table 27.39 Funding and Investment Analysis: Distribution by Application Area
Table 27.40 Funding and Investment Analysis: Most Active Players: Distribution by Number of Instances
Table 27.41 Funding and Investment Analysis: Most Active Players: Distribution by Amount Raised (USD Million)
Table 27.42 Leading Investors by Number of Funding Instances
Table 27.43 Funding and Investment Analysis: Distribution by Geography (Region)
Table 27.44 Funding and Investment Analysis: Distribution by Geography (Country) (USD Million)
Table 27.45 Big Pharma Players: Distribution by Year of Initiative
Table 27.46 Big Pharma Players: Distribution by Type of Initiative
Table 27.47 Big Pharma Players: Distribution by Year and Type of Initiative
Table 27.48 Big Pharma Players: Distribution by Number of Initiatives
Table 27.49 Big Pharma Players: Distribution by Type of Partnership
Table 27.50 Big Pharma Initiatives Summary
Table 27.51 Global Liquid Biopsy Market: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035), Base Scenario (USD Billion)
Table 27.52 Global Liquid Biopsy Market: Forecasted Estimates, Till 2035, Conservative Scenario (USD Billion)
Table 27.53 Global Liquid Biopsy Market: Forecasted Estimates, Till 2035, Optimistic Scenario (USD Billion)
Table 27.54 Liquid Biopsy Market: Distribution by Type of Technology
Table 27.55 Liquid Biopsy Market for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.56 Liquid Biopsy Market for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.57 Liquid Biopsy Market: Distribution by Type of Sample
Table 27.58 Liquid Biopsy Market for Blood, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.59 Liquid Biopsy Market for Other Samples, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.60 Liquid Biopsy Market: Distribution by Type of Circulating Biomarker
Table 27.61 Liquid Biopsy Market for Circulating Tumor DNA, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.62 Liquid Biopsy Market for Cell Free DNA, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.63 Liquid Biopsy Market for Cell Free RNA, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.64 Liquid Biopsy Market for Exosomes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.65 Liquid Biopsy Market for Other Circulating Biomarkers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.66 Liquid Biopsy Market: Distribution by Type of Cancer
Table 27.67 Liquid Biopsy Market for Breast Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.68 Liquid Biopsy Market for Colorectal Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.69 Liquid Biopsy Market for Prostate Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.70 Liquid Biopsy Market for Lung Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.71 Liquid Biopsy Market for Bladder Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.72 Liquid Biopsy Market for Melanoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.73 Liquid Biopsy Market for Thyroid Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.74 Liquid Biopsy Market for Gastric Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.75 Liquid Biopsy Market for Head and Neck Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.76 Liquid Biopsy Market for Leukemia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.77 Liquid Biopsy Market for Brain Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.78 Liquid Biopsy Market for Liver Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.79 Liquid Biopsy Market for Cervical Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.80 Liquid Biopsy Market for Ovarian Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.81 Liquid Biopsy Market for Oesophagus Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.82 Liquid Biopsy Market for Pancreatic Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.83 Liquid Biopsy Market for Nasopharyngeal cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.84 Liquid Biopsy Market for Sarcoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.85 Liquid Biopsy Market: Distribution by Application Area
Table 27.86 Liquid Biopsy Market for Early Diagnosis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.87 Liquid Biopsy Market for Patient Monitoring, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.88 Liquid Biopsy Market for Recurrence Monitoring, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.89 Liquid Biopsy Market: Distribution by End-user
Table 27.90 Liquid Biopsy Market for Hospitals / Laboratories, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.91 Liquid Biopsy Market for Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.92 Liquid Biopsy Market for Other End-users, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.93 Liquid Biopsy Market: Distribution by Geographical Regions
Table 27.94 Liquid Biopsy Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.95 Liquid Biopsy Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.96 Liquid Biopsy Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.97 Liquid Biopsy Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.98 Liquid Biopsy Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.99 Liquid Biopsy Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.100 Liquid Biopsy Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.101 Liquid Biopsy Market in Spain, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.102 Liquid Biopsy Market in Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.103 Liquid Biopsy Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.104 Liquid Biopsy Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.105 Liquid Biopsy Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 27.106 Liquid Biopsy Market in Australia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
List of Figures
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 5.1 Executive Summary: Market Landscape of Liquid Biopsy
Figure 5.2 Executive Summary: Partnerships and Collaborations
Figure 5.3 Executive Summary: Funding and Investment Analysis
Figure 5.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Worldwide Incidence of Cancer in 2025: Distribution by Target Indication
Figure 6.2 Factors to Determine Before Cancer Screening
Figure 6.3 Conventional Cancer Diagnosis Methods
Figure 6.4 Disadvantages of Invasive Techniques
Figure 6.5 Traditional Biopsy: Process Flow
Figure 6.6 Non-Invasive Tests: Process Flow
Figure 6.7 Comparison of Liquid Biopsy and Traditional Tissue Biopsy
Figure 6.8 Non-Invasive Cancer Diagnostics: Year-wise Distribution of Patents
Figure 7.1 Non-Invasive Cancer Screening and Diagnostic Techniques
Figure 7.2 Types of Diagnostic Imaging Procedures
Figure 7.3 Types of Screening Assays
Figure 7.4 Types of Advanced Non- Invasive Approaches for Cancer Diagnosis
Figure 8.1 Liquid Biopsy: Distribution by Stage of Development
Figure 8.2 Liquid Biopsy: Analysis by Type of Solution
Figure 8.3 Liquid Biopsy: Analysis by Type of Technology
Figure 8.4 Liquid Biopsy: Analysis by Type of Sample
Figure 8.5 Liquid Biopsy: Analysis by Type of Circulating Biomarker
Figure 8.6 Liquid Biopsy: Analysis by Type of Cancer
Figure 8.7 Liquid Biopsy: Analysis by Solution Purpose
Figure 8.8 Liquid Biopsy: Analysis by Application Area
Figure 8.9 Liquid Biopsy Solution Providers: Distribution by Year of Establishment
Figure 8.10 Liquid Biopsy Solution Providers: Distribution by Company Size
Figure 8.11 Liquid Biopsy Solution Providers: Distribution by Location of Headquarters
Figure 8.12 Liquid Biopsy Solution Providers: Distribution by Most Active Players
Figure 9.1 Product Competitiveness Analysis: Overview of Liquid Biopsy Assay Kits (Peer Group I)
Figure 9.2 Product Competitiveness Analysis: Overview of Liquid Biopsy Devices (Peer Group II)
Figure 9.3 Product Competitiveness Analysis: Overview of Liquid Biopsy Software and Other Solution (Peer Group III)
Figure 9.4 Product Competitiveness Analysis: Liquid Biopsy Assay Kits Offered by Providers based in North America
Figure 9.5 Product Competitiveness Analysis: Liquid Biopsy Assay Kits Offered by Providers based in Europe
Figure 9.6 Product Competitiveness Analysis: Liquid Biopsy Assay Kits Offered by Providers based in Asia- Pacific and RoW
Figure 9.7 Product Competitiveness Analysis: Liquid Biopsy Devices Offered by Providers based in North America
Figure 9.8 Product Competitiveness Analysis: Liquid Biopsy Devices Offered by Providers based in Europe
Figure 9.9 Product Competitiveness Analysis: Liquid Biopsy Devices Offered by Providers based in Asia Pacific and RoW
Figure 9.10 Product Competitiveness Analysis: Liquid Biopsy Software and Other Solutions
Figure 11.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 11.5 Partnerships and Collaborations: Distribution by Type of Circulating Biomarker
Figure 11.6 Partnerships and Collaborations: Distribution by Type of Cancer
Figure 11.7 Partnerships and Collaborations: Most Active Players: Distribution by Number of Partnerships
Figure 11.8 Partnerships and Collaborations: Local and International Agreements
Figure 11.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 12.1 Funding and Investment Analysis: Cumulative Year- wise Distribution of Funding Instances, Pre-2020-2025
Figure 12.2 Funding and Investment Analysis: Cumulative Year- wise Distribution by Amount Invested, Pre-2020-2025 (USD Million)
Figure 12.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 12.4 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding
Figure 12.5 Funding and Investment Analysis: Distribution by Year and Type of Funding, Pre 2020-2025
Figure 12.6 Funding and Investment Analysis: Distribution by Type of Circulating Biomarker
Figure 12.7 Funding and Investment Analysis: Distribution by Type of Cancer
Figure 12.8 Funding and Investment Analysis: Distribution by Application Area
Figure 12.9 Funding and Investment Analysis: Most Active Players: Distribution by Number of Instances
Figure 12.10 Funding and Investment Analysis: Most Active Players: Distribution by Amount Raised (USD Million)
Figure 12.11 Leading Investors by Number of Funding Instances
Figure 12.12 Funding and Investment Analysis: Distribution by Geography (Region)
Figure 12.13 Funding and Investment Analysis: Distribution by Geography (Country) (USD Million)
Figure 13.1 Big Pharma Players: Distribution by Year of Initiative
Figure 13.2 Big Pharma Players: Distribution by Type of Initiative
Figure 13.3 Big Pharma Players: Distribution by Year and Type of Initiative
Figure 13.4 Big Pharma Players: Distribution by Number of Initiatives
Figure 13.5 Big Pharma Players: Distribution by Type of Partnership
Figure 13.6 Big Pharma Players: Distribution by Type of Initiative
Figure 13.7 Big Pharma Players: Distribution by Year of Initiative
Figure 13.8 Big Pharma Initiatives Summary
Figure 17.1 Global Liquid Biopsy Market: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035), Base Scenario (USD Billion)
Figure 17.2 Global Liquid Biopsy Market: Forecasted Estimates, Till 2035, Conservative Scenario (USD Billion)
Figure 17.3 Global Liquid Biopsy Market: Forecasted Estimates, Till 2035, Optimistic Scenario (USD Billion)
Figure 18.1 Liquid Biopsy Market: Distribution by Type of Technology
Figure 18.2 Liquid Biopsy Market for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 18.3 Liquid Biopsy Market for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 19.1 Liquid Biopsy Market: Distribution by Type of Sample
Figure 19.2 Liquid Biopsy Market for Blood, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 19.3 Liquid Biopsy Market for Other Samples, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.1 Liquid Biopsy Market: Distribution by Type of Circulating Biomarker
Figure 20.2 Liquid Biopsy Market for Circulating Tumor DNA, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.3 Liquid Biopsy Market for Cell Free DNA, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.4 Liquid Biopsy Market for Cell Free RNA, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.5 Liquid Biopsy Market for Exosomes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.6 Liquid Biopsy Market for Other Circulating Biomarkers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.1 Liquid Biopsy Market: Distribution by Type of Cancer
Figure 21.2 Liquid Biopsy Market for Breast Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.3 Liquid Biopsy Market for Colorectal Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.4 Liquid Biopsy Market for Prostate cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.5 Liquid Biopsy Market for Lung Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.6 Liquid Biopsy Market for Bladder Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.7 Liquid Biopsy Market for Melanoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.8 Liquid Biopsy Market for Thyroid Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.9 Liquid Biopsy Market for Gastric Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.10 Liquid Biopsy Market for Head and Neck Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.11 Liquid Biopsy Market for Leukemia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.12 Liquid Biopsy Market for Brain Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.13 Liquid Biopsy Market for Liver Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.14 Liquid Biopsy Market for Cervical Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.15 Liquid Biopsy Market for Ovarian Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.16 Liquid Biopsy Market for Oesophagus Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.17 Liquid Biopsy Market for Pancreatic Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.18 Liquid Biopsy Market for Nasopharyngeal cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.19 Liquid Biopsy Market for Sarcoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.1 Liquid Biopsy Market: Distribution by Application Area
Figure 22.2 Liquid Biopsy Market for Early Diagnosis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.3 Liquid Biopsy Market for Patient Monitoring, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.4 Liquid Biopsy Market for Recurrence Monitoring, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.1 Liquid Biopsy Market: Distribution by End-user
Figure 23.2 Liquid Biopsy Market for Hospitals / Laboratories, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.3 Liquid Biopsy Market for Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.4 Liquid Biopsy Market for Other End-users, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.1 Liquid Biopsy Market: Distribution by Geographical Regions
Figure 24.2 Liquid Biopsy Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.3 Liquid Biopsy Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.4 Liquid Biopsy Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.5 Liquid Biopsy Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.6 Liquid Biopsy Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.7 Liquid Biopsy Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.8 Liquid Biopsy Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.9 Liquid Biopsy Market in Spain, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.10 Liquid Biopsy Market in Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.11 Liquid Biopsy Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.12 Liquid Biopsy Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.13 Liquid Biopsy Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.14 Liquid Biopsy Market in Australia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.15 Market Movement Analysis: Geographical Regions
Figure 24.16 Penetration-Growth (P-G) Matrix: Geographical Regions
Figure 25.1 Concluding Remarks: Market Landscape
Figure 25.2 Concluding Remarks: Partnerships and Collaborations
Figure 25.3 Concluding Remarks: Funding and Investment Analysis
Figure 25.4 Concluding Remarks: Big Pharma Initiatives
Figure 25.5 Concluding Remarks: Market Sizing and Opportunity Analysis (I/II)
Figure 25.6 Concluding Remarks: Market Sizing and Opportunity Analysis (II/II)
